TCGA-C4-A0EZ-01A-21R-A24X-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 8.968462549
- os_event
- true
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.630
- G2M_CHECKPOINT+0.580
- PANCREAS_BETA_CELLS+0.440
- MYC_TARGETS_V1+0.430
- SPERMATOGENESIS+0.400
- DNA_REPAIR+0.370
- MITOTIC_SPINDLE+0.230
- OXIDATIVE_PHOSPHORYLATION+0.200
- HEDGEHOG_SIGNALING+0.090
- KRAS_SIGNALING_DN+0.080
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.690
- TNFA_SIGNALING_VIA_NFKB-0.640
- INTERFERON_GAMMA_RESPONSE-0.630
- INFLAMMATORY_RESPONSE-0.590
- IL6_JAK_STAT3_SIGNALING-0.570
- ALLOGRAFT_REJECTION-0.540
- P53_PATHWAY-0.460
- TGF_BETA_SIGNALING-0.450
- COMPLEMENT-0.440
- IL2_STAT5_SIGNALING-0.440
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_WH5HDE0A | medulloblastoma | — | 0.958 |
| 2 | C3N-02283 | — | cohortMD1 | 0.952 |
| 3 | BS_Y8D1F5WW | medulloblastoma | — | 0.952 |
| 4 | TCGA-NK-A5D1-01A-11R-A26W-07 | — | cohortMD1 | 0.952 |
| 5 | BS_TYAYZ9ZW | medulloblastoma | — | 0.946 |
| 6 | BS_4PH1MBGR | medulloblastoma | — | 0.946 |
| 7 | BS_AM70R8RG | medulloblastoma | — | 0.945 |
| 8 | BS_HD4EJYE3 | medulloblastoma | — | 0.943 |
| 9 | BS_EFE4YEK3 | medulloblastoma | — | 0.943 |
| 10 | BS_NKRYMHEP | medulloblastoma | — | 0.942 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.630 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.580 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.440 | Cobimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.430 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.400 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.370 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.230 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.090 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.080 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.060 | Inavolisib | — uncovered |